We are live on ! Find out more
NAMS icon

NewAmsterdam Pharma
NAMS

90 hedge funds and large institutions have $1.38B invested in NewAmsterdam Pharma in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 10

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

18% more funds holding

Funds holding: 76 → 90 (+14)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0.8% less ownership

Funds ownership: 80.82% → 80.02% (-0.8%)

19% less capital invested

Capital invested by funds: $1.71B → $1.38B (-$323M)

70% less call options, than puts

Call options by funds: $18K | Put options by funds: $61K

Holders
90
Holders Change
+14
Holders Change %
+18.42%
% of All Funds
1.3%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
24
Increased
30
Reduced
17
Closed
10
Calls
$18K
Puts
$61K
Net Calls
-$43K
Net Calls Change
-$43K

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$16M
2
WP
Woodline Partners
California
+$9.7M
3
DC
Decheng Capital
California
+$8.02M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$7.7M
5
Millennium Management
Millennium Management
New York
+$4.37M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$25.2M
2
OCA
Octagon Capital Advisors
New York
-$9.65M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$5.91M
4
PCH
Polar Capital Holdings
United Kingdom
-$5.02M
5
Citadel Advisors
Citadel Advisors
Florida
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
26
Ensign Peak Advisors
Utah
$4.73M – – –
TCM
27
TimesSquare Capital Management
New York
$4.73M +$350K +17,469 +8%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$4.68M – – –
MAP
29
Moody Aldrich Partners
Massachusetts
$4.24M +$2.19M +109,400 +98%
Citadel Advisors
30
Citadel Advisors
Florida
$4.11M -$4.82M -240,180 -53%
PHP
31
Parkman Healthcare Partners
Connecticut
$2.6M -$1.3M -64,935 -32%
BBA
32
Baker Bros. Advisors
New York
$1.86M – – –
Two Sigma Investments
33
Two Sigma Investments
New York
$1.66M +$695K +34,622 +67%
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$1.65M +$1M +50,000 +140%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$1.63M +$657K +32,738 +63%
Wellington Management Group
36
Wellington Management Group
Massachusetts
$1.6M -$2.71M -135,021 -62%
Aberdeen Group
37
Aberdeen Group
United Kingdom
$1.46M +$1.52M +76,000 New
HP
38
HealthInvest Partners
Sweden
$1.46M +$1.07M +53,400 +238%
SCM
39
Superstring Capital Management
New York
$1.23M +$1.29M +64,213 New
AGP
40
Artia Global Partners
Florida
$1.04M – – –
SSA
41
Schonfeld Strategic Advisors
New York
$950K -$1.46M -72,567 -59%
BlackRock
42
BlackRock
New York
$800K +$610K +30,425 +271%
CCM
43
Cinctive Capital Management
New York
$720K +$450K +22,415 +149%
GCP
44
GSA Capital Partners
United Kingdom
$709K +$740K +36,906 New
JGC
45
J. Goldman & Co
New York
$706K -$844K -42,058 -53%
Swiss National Bank
46
Swiss National Bank
Switzerland
$674K +$704K +35,100 New
GT
47
Glenmede Trust
Pennsylvania
$521K +$290K +14,465 +114%
Goldman Sachs
48
Goldman Sachs
New York
$488K -$25.2M -1,258,068 -98%
VPC
49
Vestal Point Capital
New York
$480K +$502K +25,000 New
Morgan Stanley
50
Morgan Stanley
New York
$474K -$3.07M -152,896 -86%
1
2
3 4

NAMS Hedge Fund Activity: Q2 2024 in Review

90 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q2 2024, worth a combined $1.38B — down 19% from $1.71B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new NAMS positions and 10 closed out — a net gain of 14 holders — while 30 added to existing stakes and 17 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $16M. The largest seller was Goldman Sachs, cutting an estimated $25.2M.

  • 90 institutional investors held NewAmsterdam Pharma (NAMS) as of Q2 2024, up from 76 in Q1 2024.
  • Funds reported $1.38B of NewAmsterdam Pharma stock for Q2 2024, down 19% quarter-over-quarter.
  • 24 funds opened new NewAmsterdam Pharma positions in Q2 2024 and 10 closed out, a net change of +14 holders.
  • The largest NewAmsterdam Pharma buyer in Q2 2024 was Cormorant Asset Management, an estimated $16M added.
  • The largest NewAmsterdam Pharma seller in Q2 2024 was Goldman Sachs, an estimated $25.2M sold.

Based on aggregated 13F filings for Q2 2024.